Arrowhead Pharmaceuticals, Inc. Stock News

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc., to declare that Ionis's United States Patent No. 9,593,333 (“the '333 patent”) is invalid and not infringed by Arrowhead's pla...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President James Hamilton - Chief Medical Officer and Head of R&D Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good ...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for tauopathies including Alzheimer's disease, a progressive neurodegenerati...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 10:30 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President James Hamilton - Chief Medical Officer and Head of R&D Conference Call Participants Patrick Trucchio - H.C.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Cantor Global Healthcare Conference 2025 September 4, 2025 9:10 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Prakhar Agrawal Senior Biotech Analyst All right. Welcome, everyone.

Shares in Arrowhead Pharmaceuticals (ARWR 0.72%) rose by more than 27% in the week to Friday morning. The company's bold aim is to have "20 individual products, either partnered or wholly owned, in clinical trials or on the market by 2025," and the company moved a step closer to that aim with the signing of a global licensing and collaboration agreement with pharmaceutical giant Novartis for AR...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Citi's 2025 Biopharma Back to School Conference September 3, 2025 1:00 PM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President Conference Call Participants David Lebowitz - Citigroup Inc., Research Division Presentation David Lebowitz Research Analyst Very much and welcome again to the Citi Biopharma Conference in Boston. H...

Arrowhead stock is a Strong Buy due to significant pipeline progress, especially the upcoming FDA PDUFA review date of plozasiran for familial chylomicronemia syndrome. The PALISADE phase 3 trial for plozasiran showed robust efficacy in reducing triglycerides and acute pancreatitis risk, leading to an FDA PDUFA review date of November 18, 2025. Ongoing late-stage studies for severe hypertriglyc...